ICVAX / Immuno Cure - LARVOL DELTA

YKYY-ICVAX-101: ICVAX as a HIV Therapeutic DNA Vaccine (clinicaltrials.gov) - P1 | N=45 | Active, not recruiting | Sponsor: Immuno Cure Holding (HK) Limited | Trial completion date: Jan 2025 ➔ Jun 2025

Trial completion date • Human Immunodeficiency Virus • Infectious Disease

YKYY-ICVAX-101: ICVAX As a HIV Therapeutic DNA Vaccine (clinicaltrials.gov) - P1 | N=45 | Active, not recruiting | Sponsor: Immuno Cure Holding (HK) Limited | Trial primary completion date: Jun 2024 ➔ Sep 2024

Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease

A novel PD1-enhanced DNA vaccine in PLWH under cART: a Phase 1, randomized, double-blinded, placebo-controlled, and dose-escalation study (AIDS 2024) - "These data suggest that ICVAX in ART-suppressed PLWH is safe and immunogenic and that larger clinical trials are needed to further investigate the effects of ICVAX on reservoirs."

Clinical • P1 data • Human Immunodeficiency Virus • Infectious Disease • Pain • CD4 • PD-1

ICVAX as a HIV Therapeutic DNA Vaccine (clinicaltrials.gov) - P1 | N=45 | Active, not recruiting | Sponsor: Shenzhen Immuno Cure Biomedical Company Limited

New P1 trial • Human Immunodeficiency Virus • Infectious Disease